[go: up one dir, main page]

ATE263154T1 - Heterocyclische verbindungen und arzneimittel - Google Patents

Heterocyclische verbindungen und arzneimittel

Info

Publication number
ATE263154T1
ATE263154T1 AT95930725T AT95930725T ATE263154T1 AT E263154 T1 ATE263154 T1 AT E263154T1 AT 95930725 T AT95930725 T AT 95930725T AT 95930725 T AT95930725 T AT 95930725T AT E263154 T1 ATE263154 T1 AT E263154T1
Authority
AT
Austria
Prior art keywords
alkyl
substituted
compound
represent
hydrogen
Prior art date
Application number
AT95930725T
Other languages
English (en)
Inventor
Shoichi Chokai
Yojiro Ukai
Tomiyosi Aoki
Kyoichi Ideguchi
Original Assignee
Nippon Shinyaku Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=16685068&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE263154(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Nippon Shinyaku Co Ltd filed Critical Nippon Shinyaku Co Ltd
Application granted granted Critical
Publication of ATE263154T1 publication Critical patent/ATE263154T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/34—One oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/38—One sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/56—One oxygen atom and one sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/14—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom
    • C07D251/22—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to two ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Steroid Compounds (AREA)
AT95930725T 1994-09-09 1995-09-08 Heterocyclische verbindungen und arzneimittel ATE263154T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP21621494 1994-09-09
PCT/JP1995/001792 WO1996007641A1 (en) 1994-09-09 1995-09-08 Heterocyclic derivative and medicine

Publications (1)

Publication Number Publication Date
ATE263154T1 true ATE263154T1 (de) 2004-04-15

Family

ID=16685068

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95930725T ATE263154T1 (de) 1994-09-09 1995-09-08 Heterocyclische verbindungen und arzneimittel

Country Status (19)

Country Link
US (2) US5945426A (de)
EP (1) EP0781766B1 (de)
JP (2) JP3036079B2 (de)
KR (1) KR100358245B1 (de)
CN (1) CN1118454C (de)
AT (1) ATE263154T1 (de)
BR (1) BR9508900A (de)
CA (1) CA2199518A1 (de)
DE (1) DE69532811T2 (de)
DK (1) DK0781766T3 (de)
ES (1) ES2218552T3 (de)
FI (1) FI970967A0 (de)
HU (1) HU221855B1 (de)
MX (1) MX9701765A (de)
NO (1) NO312995B1 (de)
NZ (1) NZ292269A (de)
PT (1) PT781766E (de)
RU (1) RU2128996C1 (de)
WO (1) WO1996007641A1 (de)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1300056B1 (it) 1998-04-17 2000-04-05 Boehringer Ingelheim Italia Eterocicli con anello a 6 termini difenil-sostituiti loro procedimento di preparazione e loro impiego come farmaci
WO2000010571A1 (fr) * 1998-08-25 2000-03-02 Nippon Shinyaku Co., Ltd. Antagonistes des canaux calciques
US20040077709A1 (en) * 1999-05-31 2004-04-22 Daiichi Pharmaceutical Co., Ltd. Neuronal death inhibitors
GB0003224D0 (en) 2000-02-11 2000-04-05 Glaxo Group Ltd Chemical compounds
GB0021494D0 (en) 2000-09-01 2000-10-18 Glaxo Group Ltd Chemical comkpounds
DE60109048T2 (de) * 2000-09-08 2006-04-06 Nippon Shinyaku Co., Ltd. Verfahren zur produktion von pyrimidinderivaten und geeignete zwischenprodukte
MXPA03002362A (es) * 2000-09-19 2003-06-30 Sumitomo Chemical Co Compuestos de pirimidina y su uso.
GB0112802D0 (en) 2001-05-25 2001-07-18 Glaxo Group Ltd Pyrimidine derivatives
GB0112810D0 (en) 2001-05-25 2001-07-18 Glaxo Group Ltd Pyrimidine derivatives
GB0119477D0 (en) 2001-08-09 2001-10-03 Glaxo Group Ltd Pyrimidine derivatives
AU2003258630A1 (en) 2002-08-19 2004-03-11 Glaxo Group Limited Pyrimidine derivatives as selective cox-2 inhibitors
GB0221443D0 (en) 2002-09-16 2002-10-23 Glaxo Group Ltd Pyridine derivates
RS20050532A (en) 2003-01-14 2007-12-31 Arena Pharmaceuticals Inc., 1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prpphylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia
WO2004087712A1 (en) * 2003-03-31 2004-10-14 Council Of Scientific And Industrial Research NEW PYRIMIDINE LINKED PYRROLO[2,1-c][1,4]BENZODIAZEPINES AS POTENTIAL ANTITUMOUR AGENTS
AR045047A1 (es) * 2003-07-11 2005-10-12 Arena Pharm Inc Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos
AU2004257267B2 (en) 2003-07-14 2009-12-03 Arena Pharmaceuticals,Inc Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto
US6966680B2 (en) * 2003-11-28 2005-11-22 Edward Kratz Decorative lighting display with changeable shades and bulbs
ATE415397T1 (de) * 2004-06-04 2008-12-15 Arena Pharm Inc Substituierte aryl- und heteroarylderivate als modulatoren des stoffwechsels und für die prophylaxe und behandlung von damit in zusammenhang stehenden erkrankungen
DOP2006000010A (es) 2005-01-10 2006-07-31 Arena Pharm Inc Procedimiento para preparar eteres aromáticos
MY148521A (en) * 2005-01-10 2013-04-30 Arena Pharm Inc Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto
EA013084B1 (ru) * 2005-09-16 2010-02-26 Арена Фармасьютикалз, Инк. Модуляторы метаболизма и лечение связанных с ним нарушений
TW200811140A (en) * 2006-07-06 2008-03-01 Arena Pharm Inc Modulators of metabolism and the treatment of disorders related thereto
TW200811147A (en) * 2006-07-06 2008-03-01 Arena Pharm Inc Modulators of metabolism and the treatment of disorders related thereto
EP1941879A1 (de) * 2007-01-05 2008-07-09 PAION Deutschland GmbH Nervenschutzmittel zur Behandlung von neuronalen Schäden.
DE102007051090A1 (de) 2007-06-28 2009-01-08 Charité - Universitätsmedizin Berlin SSRI zur Behandlung neuronaler Krankheiten
EP2008653A1 (de) 2007-06-28 2008-12-31 Charité-Universitätsmedizin Berlin Serotonerge Verbindungen zur Behandlung neuronaler Krankheiten
SG10201500639TA (en) 2010-01-27 2015-03-30 Arena Pharm Inc Processes for the preparation of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid and salts thereof
CA2812061A1 (en) 2010-09-22 2012-03-29 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
UA126268C2 (uk) 2015-01-06 2022-09-14 Арена Фармасьютікалз, Інк. СПОСОБИ ЛІКУВАННЯ СТАНІВ, ПОВ'ЯЗАНИХ З РЕЦЕПТОРОМ S1P<sub>1 </sub>
DK3310760T3 (da) 2015-06-22 2022-10-24 Arena Pharm Inc Krystallinsk L-argininsalt af (R)-2-(7-(4-cyclopentyl-3-(trifluormethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3- yl)eddikesyre til anvendelse ved S1P1-receptor-associerede lidelser
US11534424B2 (en) 2017-02-16 2022-12-27 Arena Pharmaceuticals, Inc. Compounds and methods for treatment of primary biliary cholangitis
MX2020013157A (es) 2018-06-06 2021-04-29 Arena Pharm Inc Métodos de tratamiento de afecciones relacionadas con el receptor s1p1.
US11414594B2 (en) * 2019-04-09 2022-08-16 Gentex Corporation Low dimerizing viologen electrochromic compounds and devices

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3167553A (en) * 1963-05-08 1965-01-26 Searle & Co 2-amino-4-ethereal-5-methyl-6-phenylpyrimidines
BE756127A (fr) * 1969-09-12 1971-03-15 Hoechst Ag Ethers heterocycliques et leur preparation
JPS4921148B1 (de) * 1970-12-28 1974-05-30
US3937712A (en) * 1971-09-22 1976-02-10 Boehringer Ingelheim Gmbh (5-nitro-2-furyl)-pyridines
BE789099A (fr) * 1971-09-22 1973-03-21 Boehringer Sohn Ingelheim Nouveaux derives de la pyridine et procede pour les fabriquer
US4115575A (en) * 1973-02-20 1978-09-19 Ciba-Geigy Corporation 2-(3-Amino-2-hydroxy-propoxy)-pyrazines
SU1095878A3 (ru) * 1980-10-22 1984-05-30 Жансен Фармасетика Н.В. (Фирма) Способ получени производных 1-(4-арилциклогексил)пиперидина или их фармацевтически пригодных солей или их стереоизомерных форм
US4698340A (en) * 1984-07-19 1987-10-06 Fujisawa Pharmaceutical Co., Ltd. Pyrimidine derivatives, processes for preparation thereof and composition containing the same
US4727073A (en) * 1984-10-01 1988-02-23 Fujisawa Pharmaceutical Co., Ltd. Pyrimidine derivatives and composition of the same
WO1989011279A1 (en) 1988-05-16 1989-11-30 Georgia State University Foundation, Inc. Nucleic acid interacting unfused heteropolycyclic compounds
GB9012311D0 (en) * 1990-06-01 1990-07-18 Wellcome Found Pharmacologically active cns compounds
WO1992004333A1 (en) * 1990-08-31 1992-03-19 Nippon Shinyaku Co., Ltd. Pyrimidine derivative and medicine
US5294612A (en) * 1992-03-30 1994-03-15 Sterling Winthrop Inc. 6-heterocyclyl pyrazolo [3,4-d]pyrimidin-4-ones and compositions and method of use thereof
IL117659A (en) * 1995-04-13 2000-12-06 Dainippon Pharmaceutical Co Substituted 2-phenyl pyrimidino amino acetamide derivative process for preparing the same and a pharmaceutical composition containing same

Also Published As

Publication number Publication date
NZ292269A (en) 1998-09-24
ES2218552T3 (es) 2004-11-16
CN1118454C (zh) 2003-08-20
HUT77779A (hu) 1998-08-28
DE69532811T2 (de) 2005-03-17
KR970705545A (ko) 1997-10-09
EP0781766A4 (de) 1998-01-14
EP0781766B1 (de) 2004-03-31
RU2128996C1 (ru) 1999-04-20
AU3399695A (en) 1996-03-27
CA2199518A1 (en) 1996-03-14
PT781766E (pt) 2004-07-30
FI970967A7 (fi) 1997-03-07
HU221855B1 (hu) 2003-02-28
FI970967L (fi) 1997-03-07
DK0781766T3 (da) 2004-07-26
CN1157609A (zh) 1997-08-20
BR9508900A (pt) 1997-12-30
MX9701765A (es) 1997-06-28
KR100358245B1 (ko) 2003-11-28
US6191149B1 (en) 2001-02-20
JP3036079B2 (ja) 2000-04-24
NO312995B1 (no) 2002-07-29
JP3312616B2 (ja) 2002-08-12
WO1996007641A1 (en) 1996-03-14
EP0781766A1 (de) 1997-07-02
DE69532811D1 (de) 2004-05-06
NO971050D0 (no) 1997-03-07
NO971050L (no) 1997-05-09
US5945426A (en) 1999-08-31
FI970967A0 (fi) 1997-03-07
AU701395B2 (en) 1999-01-28
JP2000136184A (ja) 2000-05-16

Similar Documents

Publication Publication Date Title
ATE263154T1 (de) Heterocyclische verbindungen und arzneimittel
DE69321823D1 (de) 2-amino-1, 3- propandiolverbindung und immunosuppressium
DE60017115D1 (de) Amid-derivate und deren medizinische verwendung
ATE218573T1 (de) Substituierte 4-arylmethylene-2-imino-2,3- dihydrothiazolen, ihre derivaten, und ihre pharmazeutische verwendung
HUP0102793A2 (hu) Agydaganat kezelésére szolgáló kinazolinok és ezeket tartalmazó gyógyszerkészítmények
DE69406900D1 (de) Benzolsulfonamid-Derivate und Verfahren zur Herstellung
NO882036L (no) Fremgangsmaate for fremstilling av terapeutisk aktive heterocykliske ketoner.
DK0976748T3 (da) Pyrrolidinderivater med phospholispase A2-hæmmende aktivitet
ATE538794T1 (de) Gamma carboxyarylsubstituierte diphenylharnstoffverbindungen als p38 kinasehemmer
NZ228331A (en) Amine- and amido-containing heterocyclic compounds and pharmaceutical compositions
EP1000935A4 (de) Pyridylacrylamid-derivate und arzneimittel gegen nephritis und inhibitoren des transformierenden wachstumsfaktors beta die diese derivate enthalten
NO324219B1 (no) Fenylpyridazin-forbindelser, medisiner og farmasoytiske preparater inneholdende disse samt anvendelse av disse for fremstilling av medikamenter for behandling av sykdom
ES2124477T3 (es) Uso de un fosfato de ascorbilo y tocoferilo para la preparacion de un medicamento para el tratamiento de la pancreatitis.
DE69332366D1 (de) Arylsubstituierte heterocyclische Verbindungen
DK0485219T3 (da) Lægemidler til forebyggelse og behandling af kredsløbsorgansygdomme indeholdende spiro-3-heteroazolidinforbindelser
ES2174077T3 (es) Derivados de hidroxilamina antiisquemicos y composiciones farmaceuticas.
EP1433480A4 (de) Pyrimidinderivate enthaltendes medikament
ATE241985T1 (de) Therapeutisches mittel zur behandlung von nierenerkrankungen
TH65145A (th) อนุพันธ์ของซับสทิทิวเทด 2-พิริมิดินิล-6, 7, 8, 9-เททระไฮโดรพิริมิโด[1, 2-a]พิริมิดิน-4-โอน และ 7-พิริมิดินิล-2, 3-ไดไฮโดรอิมิดาโซ[1, 2-a]พิริมิดิน-5(1H)-โอน

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0781766

Country of ref document: EP

REN Ceased due to non-payment of the annual fee